This is very reasonable. Technically, today, it is a bit of a challenge to ensure it gets delivered in such a way as to not hurt more than it helps, and to ensure it remains active. But at this point that kind of auto-manufacturing of a therapeutic an 'engineering problem' rather than a 'scientific problem'.
as an aside: Curiously, in the lab at least, most of those therapies are delivered using a 'gutted' version of HIV (precisely because it is so good at delivering genetic payloads to humans). So there's a pretty good chance you'd be using an engineered version of HIV's own machinery to deliver a permanent anti-HIV payload to the patient's genome.
as an aside: Curiously, in the lab at least, most of those therapies are delivered using a 'gutted' version of HIV (precisely because it is so good at delivering genetic payloads to humans). So there's a pretty good chance you'd be using an engineered version of HIV's own machinery to deliver a permanent anti-HIV payload to the patient's genome.